Department / Division
Obstetrics/Gynecology / Gynecology Oncology
Durham, NC 27710
Gynecologic malignancies, premalignant disease of the cervix and vagina, radical pelvic surgery, chemotherapy, immunotherapy and radiation therapy, reconstructive pelvic surgery, laser surgery, complicated gynecologic surgery, hereditary ovarian cancer
I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer. The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women.
This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
Havrilesky, LJ; Cragun, JM; Calingaert, B; Alvarez Secord, A; Valea, FA; Clarke-Pearson, DL; Berchuck, A; Soper, JT. The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer. Gynecologic Oncology. 2007;104:401-405. (2007) Abstract
Havrilesky, LJ; Secord, AA; Bae-Jump, V; Ayeni, T; Calingaert, B; Clarke-Pearson, DL; Berchuck, A; Gehrig, PA. Outcomes in surgical stage I uterine papillary serous carcinoma. Gynecologic Oncology. 2007;105:677-682. (2007) Abstract
Havrilesky, LJ; Secord, AA; Kulasingam, S; Myers, E. Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis. Gynecologic Oncology. 2007;107:211-218. (2007) Abstract
Cragun, JM; Havrilesky, LJ; Calingaert, B; Synan, I; Secord, AA; Soper, JT; Clarke-Pearson, DL; Berchuck, A. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. Journal of Clinical Oncology. 2005;23:3668-3675. (2005) Abstract
Havrilesky, LJ; Cragun, JM; Calingaert, B; Synan, I; Secord, AA; Soper, JT; Clarke-Pearson, DL; Berchuck, A. Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. Gynecologic Oncology. 2005;99:689-695. (2005) Abstract
Havrilesky, LJ; Kulasingam, SL; Matchar, DB; Myers, ER. FDG-PET for management of cervical and ovarian cancer. Gynecologic Oncology. 2005;97:183-191. (2005) Abstract
Havrilesky, LJ; Leath, CA; Huh, W; Calingaert, B; Bentley, RC; Soper, JT; Alvarez Secord, A. Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer. Gynecologic Oncology. 2004;93:429-434. (2004) Abstract
Havrilesky, LJ; Alvarez, AA; Sayer, RA; Lancaster, JM; Soper, JT; Berchuck, A; Clarke-Pearson, DL; Rodriguez, GC; Carney, ME. Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. Gynecologic Oncology. 2003;88:51-57. (2003) Abstract
Havrilesky, LJ; Peterson, BL; Dryden, DK; Soper, JT; Clarke-Pearson, DL; Berchuck, A. Predictors of clinical outcomes in the laparoscopic management of adnexal masses. Obstetrics and Gynecology. 2003;102:243-251. (2003) Abstract